Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.5 EUR | -0.82% | +2.04% | -6.70% |
Apr. 29 | STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank reiterates its Neutral rating | ZD |
Apr. 26 | STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.70% | 557M | B+ | ||
+7.84% | 218B | B | ||
+7.35% | 183B | B- | ||
+13.04% | 134B | B- | ||
+26.03% | 106B | A- | ||
-1.33% | 61.12B | A- | ||
+4.81% | 50.89B | B+ | ||
+0.30% | 40.3B | A | ||
+2.78% | 35.53B | - | ||
+26.14% | 32.05B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SBS Stock
- Ratings Stratec SE